AlphaGen Therapeutics is pioneering the discovery, development and commercialization of innovative radioligand therapies (RLTs). With our cutting-edge technology platform, we are developing a new class of alpha RLTs for patients in China and around the world.

A New Era of Alpha

AlphaGen has secured a next-generation Pb-212 isolation technology that is strongly positioned to build a leading radiopharmaceutical platform in China.

We believe Pb-212 is the premier alpha-emitting isotope to represent the next frontier in radiopharmaceuticals:

Improved therapeutic window as a result of decreased off-target radiation in healthy tissue

Abundant raw material supply from existing stockpiles

Lower radiation activity enabling broader hospital and market access

With our global expertise and innovative capabilities, we are committed to developing highly differentiated alpha and beta radioligand therapies, aiming to improve the effectiveness of cancer treatment and enhance the quality of life for patients globally.

Partner of Choice to Drive China for Global Innovation

Our goal is to accelerate the development of and improve patient access to innovative radioligand therapies. To achieve this purpose, we partner with leading biotech / pharmaceutical companies, renowned academic research institutions, and health systems globally.

We unlock value for our strategic partners through:

We are excited by the work we do and welcome others who are passionate about driving innovation in China and around the world to join us. AlphaGen is dedicated to advancing the radiopharmaceutical field and revolutionizing cancer treatments.



Careers at AlphaGen

Together, we can bring breakthrough treatments to patients globally.

We are looking for highly qualified and motivated individuals who are excited to bring life-improving medicines to cancer patients.

At AlphaGen, we aim to navigate a host of multidisciplinary challenges—discover and develop compelling R&D programs; work closely with local and global partners to bring technologies into China and around the world; and bring a new class of life-changing therapies to an untapped market.

Join us and our team of scientists and industry leaders who have diverse perspectives and are passionate about advancing the next generation of radiopharmaceuticals and alpha radioligand therapies, and ultimately, transforming people’s lives.

Copyright © 2023 AlphaGen Therapeutics. All rights reserved.Privacy Policy



Privacy Policy

All content, design, logos and layout of this site are the property of AlphaGen Therapeutics and are protected by copyright, trademark and other laws. The provision of this report does not confer or grant any intellectual property rights in this site. The content on this site is for information purposes only and is not for investment, professional, legal or other advice. AlphaGen Therapeutics does not guarantee that the information contained in this site is accurate, complete or up-to-date. You consent to accept all risks associated with the use of this site, including any reliance on the availability, accuracy, completeness, timeliness, usefulness or appropriateness of this site or its contents. The contents of this site may not be copied, reproduced, used or modified without the express written consent from AlphaGen Therapeutics.